Precision biosciences stock.
Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 2.08 years. total yearly compensation is $4.37M, comprised of 13.8% salary and 86.2% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $81.33K. The average tenure of the management team and the board of …
Precision Biosciences Stock Earnings. The value each DTIL share was expected to gain vs. the value that each DTIL share actually gained. Precision Biosciences ( DTIL) reported Q3 2023 earnings per share (EPS) of -$0.14, beating estimates of -$0.18 by 21.37%. In the same quarter last year, Precision Biosciences 's earnings per share (EPS) was ...Precision BioSciences, Inc. : Forcasts, revenue, earnings, analysts expectations, ratios for Precision BioSciences, Inc. Stock | DTIL | US74019P1084Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. See its stock price, performance, financials, outlook, and news on Google Finance.Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.60
Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding Precision BioSciences, Inc. (DTIL) Stock Price | Stock Quote Nasdaq - MarketScreener PRECISION BIOSCIENCES, INC. Precision BioSciences, Inc. Stock …Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.
With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.
DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update. 'The first half of 2023 has been a busy time at …When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.DTIL stock, representing Precision BioSciences Inc, had an interesting performance on September 19, 2023. According to data from CNN Money, the 5 analysts offering 12-month price forecasts for DTIL have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of …The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...
Dec 1, 2023 · Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.
Nov 7, 2023 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ... DURHAM, N.C.--(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel …Precision BioSciences’ shares were up almost 30% on Jan 19 following the IND acceptance. In fact, shares of the company have gained 37% in the past year compared to the industry ’s 11.1% increase.DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of …Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ...
Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. …In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00.June 23, 2022 at 12:08 PM · 3 min read. Shares of Precision BioSciences, Inc. DTIL have remained up so far this week as the company has entered into an exclusive worldwide in vivo gene-editing ...Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee …Tuesday, April 18, 2023. Precision Biosciences Expects Approximately $158M In Cash And Cash Equivalents As Of March 31, 2023. The Company's Management Also Believes That The Existing Cash And Cash ...
We would like to show you a description here but the site won’t allow us.
Company profile page for Precision Biologics Inc including stock price, company news, press releases, executives, board members, and contact informationAug 1, 2023 · Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Precision BioSciences (DTIL – Research Report) yesterday and set a price target of $1.40.The company’s shares closed ... Nov 14, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ... The Precision BioSciences stock prediction for 2025 is currently $ 0.180111, assuming that Precision BioSciences shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -53.10% increase in the DTIL stock price.Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ...
Precision Biosciences (NASDAQ:DTIL) is a biotech company with a proprietary gene-editing platform ... then I would expect the stock price to be below current price and no higher than $10, due to ...
Precision BioSciences (Nasdaq: DTIL) has a different way to edit genes, without CRISPR. It's not a new way... It's the old way. While CRISPR technology was first described in 2012, the first experiments to discover Precision Bio's method – called meganucleases – were done in the 1970s.
The short interest in Precision Biosciences Inc (NASDAQ:DTIL) is 0.85 million shares and it means that shorts have 0.83 day (s) to cover. The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 86.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 ...Precision BioSciences (NASDAQ: DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a new hire under the Nasdaq Listing Rule 5635(c)(4). The inducement, part of their Inducement Award Plan, allows the employee …Precision BioSciences Conference Call and Webcast Information. Precision's management team will host a conference call and webcast at 8:30 a.m. ET today, Friday, November 20, 2020 to discuss the collaboration. The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, …On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest …On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest …Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Find the latest Precision BioSciences, Inc. (DTIL) stock quote, history, news and other vital information to help you with your stock trading and investing.Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...However, on July 27, BMO Capital maintained a Hold rating on Precision BioSciences (NASDAQ: DTIL). See the top stocks recommended by analysts >> DTIL market cap is currently $63.96M and has a P/E ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Soft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.
Precision BioSciences Inc Registered Shs's market capitalization is $46.27 M by 120.90 M shares outstanding. Precision BioSciences Stock Snapshot 3.34 Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. See its stock price, performance, financials, outlook, and news on Google Finance.Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Instagram:https://instagram. as techcobalt companies stockbest ai stock to buyget covered nj reviews Nov 14, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ... Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00. best home inventory software for macfmna stock Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ... tastytrade futures options After the upgrade, the consensus from Precision BioSciences' five analysts is for revenues of US$37m in 2023, which would reflect a chunky 20% decline in sales compared to the last year of ...DTIL (Precision BioSciences Inc.): A Small Biotech Company with Fluctuating Earnings and Revenue Growth. DTIL (Precision BioSciences Inc.) is a biotechnology company that specializes in gene editing and gene therapy. On September 12, 2023, the stock opened at $0.41, slightly lower than the previous day’s closing price …